21 names are moving together; 90% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| BAX | Baxter International Inc. | Healthcare | +1.6% | Group member |
| STE | STERIS plc (Ireland) | Healthcare | +1.3% | Group member |
| IDXX | IDEXX Laboratories, Inc. | Healthcare | +3.0% | Group member |
| MDT | Medtronic plc. | Healthcare | +1.5% | Group member |
| ZBH | Zimmer Biomet Holdings, Inc. | Healthcare | -1.1% | Group member |
| SYK | Stryker Corporation | Healthcare | +1.6% | Group member |
| SNN | Smith & Nephew SNATS, Inc. | Healthcare | +3.2% | Group member |
| BDX | Becton, Dickinson and Company | Healthcare | +2.7% | Group member |
| ISRG | Intuitive Surgical, Inc. | Healthcare | +2.4% | Group member |
| PODD | Insulet Corporation | Healthcare | +0.1% | Group member |
| QGEN | Qiagen N.V. | Healthcare | -0.5% | Group member |
| MMSI | Merit Medical Systems, Inc. | Healthcare | +2.9% | Group member |
| SHC | Sotera Health Company | Healthcare | +2.2% | Group member |
| PHG | Koninklijke Philips N.V. NY Reg | Healthcare | +3.7% | Most structurally connected |
| GEHC | GE HealthCare Technologies Inc. | Healthcare | +2.5% | Group member |
| GMED | Globus Medical, Inc. | Healthcare | +3.7% | Group member |
| RMD | ResMed Inc. | Healthcare | +2.7% | Group member |
| PEN | Penumbra, Inc. | Healthcare | +0.2% | Group member |
| ABT | Abbott Laboratories | Healthcare | +0.3% | Group member |
| BSX | Boston Scientific Corporation | Healthcare | +1.0% | Group member |
| ITGR | Integer Holdings Corporation | Healthcare | +2.6% | Group member |
Cohort
21 namesParticipation
90% this sessionObserved history
1 daily buildsFiling coverage
18/21 memberscredit / rates affecting interest expense
“Interest Expense, net Interest expense, net increased by $19 million to $68 million in the first quarter of 2026 primarily due to interest on debt related to the acquisition of Exact Sciences, partially offset by interest income on bond proceeds and prior year debt repayments.”
ABT 10-Q
product pipeline / R&D affecting expense
“Research and development expense as a percentage of revenues in the third quarter of 2025 was flat compared with the third quarter of 2024 which primarily reflected costs attributable to the Advanced Patient Monitoring unit, offset by the timing of project spending.”
BDX 10-Q
demand / volume affecting revenue
“The increase in total net sales in 2024, excluding the impact of foreign exchange, primarily reflects higher sales in the Medical Devices, Established Pharmaceutical Products, and Nutritional Products segments, partially offset by a decrease in demand for Abbott’s rapid diagnostic tests to detect COVID-19.”
ABT 10-K
Medical Devices & Supplies can stay leader-led if MDT and the next software names fail to join while PHG keeps moving.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.